Computational and in vitro investigation of miRNA-gene regulations in retinoblastoma pathogenesis: Mirna mimics strategy

Bioinformatics and Biology Insights

Volumn 9, Issue , 2015, Pages 89-101

  Venkatesan, Nalini ^a,b   Deepa, Perinkulam Ravi ^b   Khetan, Vikas ^c   Krishnakumar, Subramanian ^a  

^a VISION RESEARCH FOUNDATION   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^c MEDICAL RESEARCH FOUNDATION   (India)

Author keywords

Mimics; MiRNA mRNA; Retinoblastoma; Sords: bio informatics analysis

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD24 ANTIGEN; HERMES ANTIGEN; HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA; MICRORNA 142 5P; MICRORNA 146 5P; MICRORNA 146B; MICRORNA 328; MICRORNA 486 3P; MICRORNA 532 5P; PROTEIN KINASE SYK; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ABCG2 GENE; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER CELL LINE; CANCER PROGNOSIS; CANCER STEM CELL; CD133 GENE; CD24 GENE; CD44 GENE; CELL CYCLE; CELL CYCLE PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DATA BASE; DOWN REGULATION; ENERGY; FASN GENE; GENE CONTROL; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HMGA2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MATHEMATICAL ANALYSIS; MDM2 GENE; MICROCOSM; MIR 1254 GENE; MIR 1287 GENE; MIR 1299 GENE; MIR 133A GENE; MIR 142 5P GENE; MIR 146B 5P GENE; MIR 299 GENE; MIR 305 GENE; MIR 328 GENE; MIR 375 GENE; MIR 486 3P GENE; MIR 501 GENE; MIR 513B GENE; MIR 532 5P GENE; MIR 663B GENE; MIR 892B GENE; MYCN GENE; ONCOGENE; PATHOGENESIS; PICTAR SCORE; PRACTICE GUIDELINE; PREDICTION; PROTEIN EXPRESSION; QUANTITATIVE STUDY; RATING SCALE; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; RNA ISOLATION; SCORING SYSTEM; SEQUENCE ALIGNMENT; SYK GENE; TACSTD GENE; TRANSCRIPTION REGULATION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

EID: 84930615980     PISSN: None     EISSN: 11779322     Source Type: Journal    
DOI: 10.4137/BBIi.Ss21742.     Document Type: Article

References (43)

1. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009;136(4):642–55
2. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308): 835–40
3. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12(2):99–110
4. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008;283(2):1026–33
5. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124(6):1169–81
6. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60
7. Hammond SM. MicroRNAs as tumor suppressors. Nat Genet. 2007;39(5): 582–3
8. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403(6772):901–6
9. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105
10. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27(1):91–105
11. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495–500
12. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol. 2004;2(11):e363
13. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 2010;11(8):R90
14. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10):1278–84
15. Li Y, Liang C, Wong KC, Jin K, Zhang Z. Inferring probabilistic miRNA-mRNA interaction signatures in cancers: a role-switch approach. Nucleic Acids Res. 2014;42(9):e76
16. Thomson DW, Bracken CP, Goodall GJ. Experimental strategies for microRNA target identification. Nucleic Acids Res. 2011;39(16):6845–53
17. Balla MM, Vemuganti GK, Kannabiran C, Honavar SG, Murthy R. Phenotypic characterization of retinoblastoma for the presence of putative cancer stem-like cell markers by flow cytometry. Invest Ophthalmol Vis Sci. 2009;50(4):1506–14
18. Castéra L, Sabbagh A, Dehainault C, et al. MDM2 as a modifier gene in retinoblastoma. J Natl Cancer Inst. 2010;102(23):1805–8
19. Felsher DW. Role of MYCN in retinoblastoma. Lancet Oncol. 2013;14(4):270–1
20. Li J, Li C, Yuan H, Gong F. Clinical value of CD24 expression in retinoblastoma. J Biomed Biotechnol. 2012;2012:158084
21. Mitra M, Kandalam M, Harilal A, et al. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Mol Vis. 2012;18:290–308
22. Mohan A, Kandalam M, Ramkumar HL, Gopal L, Krishnakumar S. Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthalmol. 2006;90(7):889–93
23. Vandhana S, Deepa PR, Jayanthi U, Biswas J, Krishnakumar S. Clinico- pathological correlations of fatty acid synthase expression in retinoblastoma: an Indian cohort study. Exp Mol Pathol. 2011;90(1):29–37
24. Venkatesan N, Kandalam M, Pasricha G, et al. Expression of high mobility group A2 protein in retinoblastoma and its association with clinicopathologic features. J Pediatr Hematol Oncol. 2009;31(3):209–14
25. Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481(7381):329–34
26. Sastre X, Chantada GL, Doz F, et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133(8):1199–202
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8
28. Beta M, Venkatesan N, Vasudevan M, Vetrivel U, Khetan V, Krishnakumar S. Identification and Insilico Analysis of Retinoblastoma Serum microRNA Profile and Gene Targets Towards Prediction of Novel Serum Biomarkers. Bioinform Biol Insights. 2013;7:21–34
29. Stempor PA, Cauchi M, Wilson P. MMpred: functional miRNA–mRNA interaction analyses by miRNA expression prediction. BMC Genomics. 2012;13:620
30. Seigler HF. Immunodiagnosis of human malignancy. Ann Surg. 1985;201(4):415–22
31. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108(9):3713–8
32. Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011;11:374
33. Oh HK, Tan AL, Das K, et al. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res. 2011;17(9):2657–67
34. Redova M, Poprach A, Besse A, et al. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol. 2013;34(1):481–91
35. Akbari Moqadam F, Pieters R, den Boer ML. The hunting of targets: challenge in miRNA research. Leukemia. 2013;27(1):16–23
36. Coopman PJ, Do MT, Barth M, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature. 2000;406(6797):742–7
37. Deepa PR, Vandhana S, Krishnakumar S. Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells. Nutr Cancer. 2013;65(2):311–6
38. Vandhana S, Coral K, Jayanthi U, Deepa PR, Krishnakumar S. Biochemical changes accompanying apoptotic cell death in retinoblastoma cancer cells treated with lipogenic enzyme inhibitors. Biochim Biophys Acta. 2013;1831(9):1458–66
39. Deepa PR, Vandhana S, Muthukumaran S, Umashankar V, Jayanthi U, Krishnakumar S. Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells. J Ocul Biol Dis Infor. 2010;3(4):117–28
40. Wang JC, Bégin LR, Bérubé NG, et al. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res. 2007;13(8):2354–61
41. Friesland A, Zhao Y, Chen YH, Wang L, Zhou H, Lu Q. Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. Proc Natl Acad Sci U S A. 2013;110(4):1261–6
42. Seong I, Min HJ, Lee JH, et al. Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes. PLoS One. 2012;7(2):e31477
43. Li HP, Huang HY, Lai YR, et al. Silencing of miRNA-148a by hypermethylation activates the integrin-mediated signaling pathway in nasopharyngeal carcinoma. Oncotarget. 2014;5(17):7610–24.